The Medipattern Corporation

The Medipattern Corporation

November 09, 2005 06:30 ET

Medipattern Successfully Achieves ISO 13485 and CMDCAS Registration

TORONTO, ONTARIO--(CCNMatthews - Nov. 9, 2005) -

Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), a leading developer of computer-aided detection (CAD) software applications for medical imaging, today announced the successful registration of its Quality Management System to both the ISO 13485:2003 standard and the requirements of the Canadian Medical Devices Conformity Assessment System (CMDCAS). The scope of the registration covers processes for design, development, manufacture, installation and servicing of software for radiology, thereby enabling larger market penetration for Medipattern's B-CAD™ software for breast ultrasound.

"The registration of the Quality Management System governing our design and development provides us with third-party validation of our systems and processes. It also reflects Medipattern's commitment to customers to ensure our software meets the highest international regulatory standards," said Jeff Collins, President and CEO of The Medipattern Corporation. "With this certificate in hand, we are strongly positioned for the commercial adoption of our products internationally."

The ISO 13485:2003 standard is the medical-device-specific standard based on ISO 9001. Registration to this standard indicates that a company has Quality Management System processes in place that have been assessed for their ability to meet customer and regulatory requirements. Health Canada requires medical device manufacturers to obtain a quality system certificate as evidence of compliance to the appropriate regulatory and quality system requirements. Health Canada will only accept quality system certificates that have been issued by special third-party auditing organizations under the Canadian Medical Devices Conformity Assessment System (CMDCAS).

Upcoming Presentations by Medipattern

- Medipattern will be demonstrating its B-CAD software in both the Cedara Software and Merge Healthcare booths at the RSNA Annual Meeting from November 27 to December 2, 2005, at McCormick Place in Chicago at Booth Numbers 1315 and 1918 respectively.

About The Medipattern Corporation

The Medipattern Corporation develops computer-aided detection (CAD) software applications for medical imaging. Medipattern's core technology is a software platform designed to analyze and automate the processing of medical digital images. Medipattern's initial clinical application is CAD for breast ultrasound (B-CAD™). B-CAD uses pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in ultrasound images of the breast. For additional information, please visit Medipattern's website at:

B-CAD™ is a trademark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's financial performance, operations, or operating environment that are based on Medipattern's operations, estimates, forecasts, and projections. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, or are beyond the company's control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. These factors include those set forth in the company's corporate filings (posted at Consequently, readers should not rely on such forward-looking statements. In addition, these forward-looking statements relate to the date on which they are made. Although the forward-looking statements contained herein are based upon what management believes to be reasonable assumptions, Medipattern cannot be certain that actual results will be consistent with these forward-looking statements, and the company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

The TSX Venture Exchange has in no way passed on the merits of the transaction described herein.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information

  • The Medipattern Corporation
    Jeff Collins
    President & CEO
    (416) 744-0009 ext. 224
    Ciris Investor Relations
    Robin Sundstrom
    (416) 368-8770 x223
    Ciris Public Relations
    Jeff Lake
    (905) 617-0413